Saturday, February 7, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Truist Securities Analyst Michael Ciarmoli Reaffirms Buy Rating on AerSale with Adjusted Price Target

Elaine Mendonca by Elaine Mendonca
March 11, 2024
in Breaking News
0
Finance_ Investing in stocks
0
SHARES
4
VIEWS
Share on FacebookShare on Twitter

On March 11, 2024, Truist Securities analyst Michael Ciarmoli reaffirmed his positive stance on AerSale (NASDAQ: ASLE) with a Buy rating. However, he has adjusted the price target for the stock, setting it at $12 instead of the previous $19. Ciarmoli, known for his success rate of 71.05% and an average return of 13.76% in covering various stocks, is ranked #279 out of 4,342 analysts. His expertise and experience in stock analysis are evident in his track record.

ASLE Stock Declines 2.94% on March 11, 2024: Whats Next for Investors?

On March 11, 2024, ASLE stock experienced a decline in its price performance. Trading near the bottom of its 52-week range and below its 200-day simple moving average, the stock opened at $7.02, which was $0.05 higher than its previous close. Throughout the trading day, ASLE shares saw a decrease of $0.21, resulting in a 2.94% drop in its price. This downward trend may have been influenced by various factors such as market conditions, company news, or investor sentiment. Investors and analysts will be closely monitoring ASLE’s performance in the coming days to see if the stock can rebound from its recent decline. It will be important to watch for any potential catalysts that could impact the stock’s price movement, as well as keeping an eye on overall market trends.

ASLE Stock Performance Review: Revenue Decline and Net Income Increase on March 11, 2024

On March 11, 2024, ASLE stock experienced mixed performances based on the financial data provided by CNN Money. The total revenue for the company was reported at $334.50 million for the past year, with a significant decrease of 18.12% compared to the previous year. However, the total revenue remained flat since the last quarter at $94.42 million. The net income for ASLE was reported at -$5.56 million for the past year, showing a significant decrease of 112.68% compared to the previous year. On a positive note, the net income increased by 0.0% since the last quarter, reaching -$2.73 million. Earnings per share (EPS) for ASLE were reported at -$0.11 for the past year, showing a decrease of 113.15% compared to the previous year. The EPS remained unchanged since the last quarter at -$0.05. Overall, the financial performance of ASLE on March 11, 2024, showed a mixed picture. Investors and analysts may need to closely monitor the company’s financial performance and market trends to make informed decisions regarding ASLE stock.

Tags: ASLE
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Telecommunications Industry Stock Exchange

Analyzing Entravision Communications Dividend Payouts and Strategies

A couple

The Rise of Empathetic Partnerships: Understanding Menstrual Cycles Through Tech

AI

Exploring the Rise of AI in Empowering Business and Personal Growth: Trends and Innovations

Recommended

Super Micro Computer Stock

Super Micro Stock Surges Amid AI Infrastructure Boom

4 months ago
Adobe Stock

Adobe’s AI Ambitions Face Investor Skepticism

4 months ago
IBM Stock

Strong IBM Earnings Fail to Impress Market as Key Segment Shows Weakness

4 months ago
Inozyme Pharma Inc Stock

Inozyme Pharma Acquisition Finalized: Strategic Focus Shifts to Clinical Development

5 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Myers Industries Set to Report Full-Year and Q4 2025 Results

OneSpan Strengthens Mobile Security Arsenal with Strategic Acquisition

Riley Exploration Permian Bolsters Board with Industry Veteran Amid Shareholder Activity

Great Lakes Dredge & Dock: A Cash Flow Inflection Point Approaches

Investors Await March Report for Boston Omaha’s Strategic Direction

Universal Insurance Maintains Quarterly Payout Amid Sector Headwinds

Trending

Orthofix Medical Stock
Earnings

Orthofix Medical Strengthens Scientific Foundation for Biologics Portfolio

by Rodolfo Hanigan
February 7, 2026
0

Investor attention turns to Orthofix Medical as the company bolsters the clinical support for its biologics business...

CrossFirst Bankshares Stock

A New Chapter for First Busey as CrossFirst Merger Finalizes

February 7, 2026
Golden Entertainment Stock

Golden Entertainment to Exit Public Markets in Strategic Privatization Deal

February 7, 2026
Myers Industries Stock

Myers Industries Set to Report Full-Year and Q4 2025 Results

February 7, 2026
OneSpan Stock

OneSpan Strengthens Mobile Security Arsenal with Strategic Acquisition

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Orthofix Medical Strengthens Scientific Foundation for Biologics Portfolio
  • A New Chapter for First Busey as CrossFirst Merger Finalizes
  • Golden Entertainment to Exit Public Markets in Strategic Privatization Deal

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com